Liquidia

Liquidia's mission is to develop best-in-class therapies for rare cardiopulmonary diseases, helping patients breathe easier and live longer. The company has successfully transitioned from a technology platform to a commercial entity with the FDA approval and launch of YUTREPIA™ for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its strategy centers on maximizing the commercial potential of YUTREPIA™, advancing its pipeline through clinical development, and exploiting the versatility of its PRINT® platform for future inhaled therapeutics.

PRINT® (Particle Replication In Non-wetting Templates) is a proprietary particle engineering platform that enables precise design and manufacture of drug particles with control over size, shape, composition, and surface functionality, optimizing them for targeted drug delivery, particularly to the lung.

Liquidia's main competitor is United Therapeutics' Tyvaso® (nebulized treprostinil). The competitive battle centers on delivery convenience, with YUTREPIA™'s dry powder inhaler offering faster, more portable administration. The broader market includes oral therapies from Actelion, Bayer, and Pfizer, with Merck's Sotatercept representing a potential future competitive threat.